The ATP8B1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cell line, engineered for targeted disruption of the ATP8B1 gene. This product provides a heterogeneous loss-of-function model that circumvents clonal selection artifacts, enabling population-level studies of ATP8B1-dependent processes. Designed for functional genomics and drug discovery applications, these cells offer a robust platform for investigating phospholipid flippase biology in an epithelial context.
The HeLa host cell line, originally isolated from a human cervical adenocarcinoma, has been extensively characterized in cell biology research. These epithelial cells exhibit rapid proliferation, stable karyotype, and well-defined membrane trafficking and apoptosis pathways. Their native expression of endocytic machinery, adhesion proteins, and signaling regulators makes HeLa a relevant model for dissecting ATP8B1??s role in maintaining plasma membrane asymmetry and its impact on cellular functions such as migration and drug response.
ATP8B1 is a P4-ATPase phospholipid flippase that forms a heterodimeric complex with the accessory subunit CDC50A (TMEM30A) to translocate phosphatidylserine (PS) and phosphatidylethanolamine from the exoplasmic to the cytoplasmic leaflet, preserving membrane lipid asymmetry. The flippase is activated by membrane curvature and regulated through protein?Cprotein interactions. Downstream, ATP8B1-dependent lipid organization is critical for AP2 adaptor recruitment during endocytosis, E-cadherin stabilization at adhesion junctions, and controlled PS externalization during apoptosis. PS exposure serves as an ??eat-me?? signal for phagocytes and modulates immune recognition. In non-hepatic cells like HeLa, ATP8B1 regulation may diverge from hepatocyte FXR-mediated transcriptional control, relying more on post-translational mechanisms. The ATP8B1?CCDC50A?CPS axis thus integrates membrane dynamics with key cellular decisions.
In HeLa cells, ATP8B1 knockout disrupts phospholipid asymmetry, leading to constitutive PS exposure that can alter endocytic trafficking and impair cell migration. This phenotype is particularly relevant to cancer biology, where PS externalization is often hijacked for immune evasion and may contribute to drug resistance by suppressing apoptosis. Although ATP8B1 mutations are linked to progressive familial intrahepatic cholestasis, the HeLa model provides a simplified system to study flippase function without the confounding influence of bile acid homeostasis, enabling focused investigations of membrane remodeling in epithelial pathologies.
The polyclonal knockout cells are suited for a wide range of assays, including Annexin V staining to monitor PS exposure, biochemical flippase activity measurements, western blotting, and immunofluorescence localization. Endocytosis can be tracked using fluorophore-conjugated transferrin or EGF, and apoptosis assessed via caspase activation assays. Co-immunoprecipitation validates ATP8B1?CCDC50A complex formation, while cell migration and wound-healing assays explore flippase contributions to motility. These applications support research in membrane biology, cancer progression, and drug resistance. For further information, please contact Ascent Research.
